Max Character Limit 45

Max Character Limit 45

Bring Biologics to Market Quickly and Cost Effectively

Article: In-House Versus Outsource: A Decision-Making Guide

Think using a CDMO is only a fit for small firms with no resources to manufacture products in-house? Not quite.

Big, medium, or small, if you're looking to accelerate drug development, streamline scale up, respond quickly to capacity changes, and tap into deep drug development and process expertise, then the use of a CDMO may be worth considering.

Download this guide to help you decide if you're truly ready to handle the following in-house:

  • Complicated therapeutic compounds: from antibody-drug conjugates and fusion proteins to glycoengineered mAbs and bispecific mAbs, are your facilities ready?
  • Rigorous regulatory approval processes: do you have everything you need to ensure a smooth regulatory pathway?
  • The uncertainty of forecasting: consequences could mean either patients will be short of critical medication or the oversupply will be expensive and wasteful.

Bonus: If you decide you may need to use a CDMO, this guide includes a list of qualification questions to ask when narrowing down your options.

Download the article